Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
 
Articles by Pradeep Das
Total Records ( 2 ) for Pradeep Das
  Krishna Murti , Manoj Kumar Sethi , Akalanka Dey , Chandra Sekhar Lal , Krishna Pandey and Pradeep Das
  This study compares the change in BMI, fasting and postprandial blood glucose, glycosylated haemoglobin (HbA1c), Glomerular Filtration Rate (GFR), serum creatinine, blood urea and lipid profile levels when two different therapies (group A = metformin+glimepiride) and group B = metformin+glimepiride+voglibose) are given to diabetic patients to compare efficacy of voglibose as an add-on therapy. This study was a 10 months prospective, open-label comparative study. Type II diabetic subjects, aged >18 years were selected and were divided into group A and B. All the parameters were evaluated before the treatment and reassessed after 3 months of treatment. Group A and B was having significant decrease in BMI with p<0.017 and p<0.049, respectively. In both of the groups glucose triad levels decreased significantly as p value found less than 0.05. There was no effect was found over blood urea level. Protective function of kidney observed when voglibose added. Evidence of controlling lipid profile also observed in triple drug therapy as p-value was <0.05. The add-on therapy using voglibose in dual therapy including glimepiride and metformin showed a very significant benefit in controlling the glucose triad levels (HbA1C, fasting plasma glucose and postprandial glucose level) when compared to dual therapy. Voglibose has an effect to decrease Total Cholesterol (TC), triglycerides (TGs) and Low Density Lipoproteins (LDL) level and increase HDL significantly. There was no effect was found on blood urea level.
  Elisson Romanel , Pradeep Das , Richard M. Amasino , Jan Traas , Elliot Meyerowitz and Marcio Alves-Ferreira
  Stamens undergo a very elaborate development program that gives rise not only to many specific tissue types, but also to the male gametes. The specification of stamen identity is coordinated by a group of homeotic genes such as APETALA3 (AP3) and PISTILLATA (PI), AGAMOUS (AG) and SEPALLATA (SEP1-4) genes. Genome-wide transcriptomic comparisons between floral buds of wild-type and ap3 mutants led to the identification of the REM22 gene, which is expressed in the early stages of stamen development. This gene is member of the plant-specific B3 DNA-binding superfamily. In this work, we dissect the spatio-temporal expression pattern of REM22 during the early stages of stamen development. To this end, both in situ hybridization analyses as well as in vivo fluorescence strategies were employed. At stage 4 of flower development, REM22 is expressed exclusively in those undifferentiated cells of the floral meristem that will give rise to the stamen primordia. At stage 5, REM22 expression is restricted to the epidermal and the subepidermal layers of anther primordia. Later, this expression is confined to the middle layer and the differentiating tapetal cells. After stage 10 when all the tissues of the anther have differentiated, REM22 expression is no longer detectable. Furthermore, we examined the pREM22::GUS-GFP marker line in an inducible system where the ectopic AG function is used to promote microsporogenesis. The data support the idea that REM22 expression is a useful marker to study the early stages of stamen development.
 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility